Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
People treated for hepatitis C have unexpectedly high rate of liver cancer recurrence

Hepatitis C patients with cirrhosis who were treated with direct-acting antivirals had about twice the expected likelihood of developing hepatocellular carcinoma (HCC), with the excess risk seen

Published
29 April 2016
By
Liz Highleyman
Portugal's roll-out of HCV therapy with DAAs achieves impressive results

Roll-out of hepatitis C virus (HCV) therapy using direct acting antivirals (DAAs) has achieved excellent outcomes in Portugal, data presented to the International Liver Congress in Barcelona shows.

Published
27 April 2016
By
Michael Carter
New York Insurers to Change Coverage of Hepatitis C Drugs

Seven health-insurance companies in New York will change their criteria for covering costly drugs that cure chronic hepatitis C under the terms of agreements with the office of State Attorney General Eric Schneiderman.

Published
26 April 2016
From
Wall Street Journal
AIDS expert to head $5-million research efforts on hepatitis C

Health Minister Terry Lake on Thursday announced a $5-million study that will look at how to reduce the spread of hepatitis C among intravenous drug users, sex workers and men who have sex with men. It will concentrate on people who have already taken medication that clears them of the hepatitis C virus, but who could be reinfected if they have blood-to-blood contact with another person. They will be encouraged to prevent that by using condoms, not sharing needles and taking part in support programs through Vancouver Coastal Health, one of the five organizations involved in the program.

Published
22 April 2016
From
Vancouver Sun
DAAs achieve excellent outcomes in real-world settings

Hepatitis C virus (HCV) therapy with direct acting antivirals (DAAs) is as effective in real-world settings as it was in clinical trials, according to US research presented

Published
21 April 2016
By
Michael Carter
Sofosbuvir/velpatasvir cures HCV in 95% of people with HCV and HIV co-infection

A dual regimen of sofosbuvir plus velpatasvir was well tolerated and highly effective against hepatitis C virus (HCV) genotypes 1 through 4 in HIV-positive people with chronic

Published
19 April 2016
By
Liz Highleyman
Hepatitis C: no more treatment rationing; universal access to generic medicines everywhere!

People with hepatitis C virus (HCV) and their allies from Spain and around the world have gathered at the International Liver Congress to protest the outrageous price of life-saving HCV medicines. They are pushing for generic competition to bring down the price of HCV treatment and ensure universal access.

Published
18 April 2016
From
Treatment Action Group
Six weeks of sofosbuvir/ledipasvir is enough to cure acute hepatitis C in HIV-negative people

A regimen of sofosbuvir/ledipasvir (Harvoni) taken for six weeks cured all patients with genotype 1 acute hepatitis C virus (HCV) infection, including those with high viral loads,

Published
18 April 2016
By
Liz Highleyman
Low-cost generic hepatitis C drugs match branded products in viral response

Generic versions of direct-acting antivirals purchased from China and India by people unable to obtain treatment in their own countries were just as effective and safe as

Published
16 April 2016
By
Keith Alcorn
Sofosbuvir/velpatasvir + GS-9857 works well for treatment-experienced hepatitis C patients

A triple combination of Gilead Sciences' sofosbuvir, velpatasvir and GS-9857 demonstrated a high sustained response rate for treatment-experienced people with all hepatitis C virus (HCV) genotypes who previously

Published
15 April 2016
By
Liz Highleyman
← First12345...75Next →

Filter by country